Ann E. Berman CPA, MBA
Ms. Berman has served as a member of our board of directors since July 2021. She currently serves as a member of the board of directors of Loews Corporation and Renalytix plc and a member of the board of trustees of Beth Israel Deaconess Medical Center and is the Chairwoman of its Compliance and Risk Committee. From September 2011 until June 2021, Ms. Berman served as a member of the board of directors and Chair of the Audit Committee of Cantel Medical Corp. In addition, she served as a member of the board of directors and Chair of the Audit Committee of Eaton Vance Corporation from February 2006 until March 2021. Prior to these roles, Ms. Berman served in various financial and risk management capacities at Harvard University, including as Senior Advisor to the President of Harvard University, Vice President of Finance and Chief Financial Officer. She received her B.A. with distinction in French language and literature from Cornell University, where she was Phi Beta Kappa, and her M.B.A. from the University of Pennsylvania's Wharton School of Business. We believe that Ms. Berman is qualified to serve on our board of directors due to her accounting and financial management expertise as a Certified Public Accountant, experience as Chief Financial Officer of a major research university, service as an audit committee member and chair of other public companies, and depth of experience in risk management.
Independent Director
Robert J. Carpenter M.S., MBA
Mr. Carpenter has served on our board of directors since May 2009. Mr. Carpenter also currently serves as the Chairman of Hydra Biosciences, Inc., or Hydra Biosciences, a privately held clinical-stage biopharmaceutical company. From 1992 until 2015, he served as the Chief Executive Officer of Boston Medical Investors, Inc., a venture capital firm. Mr. Carpenter has founded and served in executive management and board roles at numerous biotechnology companies, including Olaris Inc., Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme Corporation, and VacTex Corp., which was acquired by Aquila Biopharmaceuticals, Inc. Mr. Carpenter received his B.S. in engineering from the U.S. Military Academy at West Point, his M.S. in computer science from Stanford University and his M.B.A. from Harvard Business School.
Chairman of the Board
Peter Feinberg
Peter Feinberg has served on our Board of Directors since January 2021. Mr. Feinberg also currently serves as Partner and was a Founding Member of Boxcar Partners, a venture capital investment firm with a focus on biotechnology investing, and Founder of Sporos Bioventures, Inc. In addition, he currently serves as Co-Founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company focusing on genetic diseases, Boxcar PMJ LP and Emerging Security Solutions. He has more than three decades of experience in the financial services industry at Oppenheimer & Co. Inc. where he served as a Managing Director. Mr. Feinberg received his B.S. in finance from Whittier College. We believe that Mr. Feinberg is qualified to serve on our Board of Directors due to his extensive leadership skills and experience in the financial and biotechnology industries.
Dr. Diana Hausman, M.D.

Dr. Diana Hausman, MD, has served on our board of directors since January 2022. Dr. Hausman is a board-certified medical oncologist with over 20 years of clinical drug development experience. Since March 2022, Dr. Hausman has been the Chief Medical Officer of Link Immunotherapeutics, Inc. From June 2021 to March 2022, Dr. Hausman was the Chief Medical Officer of Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology and now a wholly-owned subsidiary of Blueprint Medicines Corporation. While at Lengo, she was responsible for all aspects of clinical development, including successful filing of the initial IND for BLU-451 (formerly LNG-451), a CNS-penetrant, EGFR Exon20 insertion inhibitor. Prior to joining Lengo, Dr. Hausman served as Chief Medical Officer for Zymeworks Inc., for 5 years from June 2016 to May 2021. While there, she oversaw all aspects of clinical development, including that of the HER2-targeted biparatopic antibody zanidatamab, from initial IND to multiple ongoing global Phase 2 and pivotal studies, with breakthrough therapy designation for treatment of biliary tract cancer. Dr. Hausman also participated actively in Zymeworks’ IPO, as well as the ongoing collaboration with Beigene. Dr. Hausman was previously CMO at Oncothyreon Inc where she oversaw the Phase 1b and early Phase 2 clinical program for the HER2-targeted small molecule, tucatinib. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle, WA. She received her MD degree from the University of Pennsylvania, Philadelphia, PA, and an A.B in biology from Princeton University, Princeton, NJ.

Independent Director
Laurie B. Keating J.D.
Laurie B. Keating has served on our Board of Directors since March 2021. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., from March 2019 until September 2021, and also served as its Senior Vice President, General Counsel and Secretary from September 2014 until March 2019. From September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Ms. Keating currently serves on the board of directors of two clinical-stage biopharmaceutical companies, Imago BioSciences (Nasdaq:IMGO), where she serves on the Audit Committee, and PepGen Inc. (Nasdaq:PEPG), where she is Chair of the Board, Chair of the Compensation Committee and a member of the Audit and Nominating and Corporate Governance committees. From 2005 until March 2022 she served on the Board of Directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law. We believe that Ms. Keating is qualified to serve on our Board of Directors due to her extensive leadership skills and experience in the biotechnology industry.
Independent Director
Benjamin J. Zeskind Ph.D.
Dr. Zeskind has served as our Co-Founder, President, Chief Executive Officer and a member of our board of directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.
Print Page
Email Alerts
Email Page
RSS Feeds